Rosiglitazone and Its Effects on Liver Fat in Rats
Author Information
Author(s): Yang Soo Jin, Choi Jung Mook, Chae Seoung Wan, Kim Won Jun, Park Se Eun, Rhee Eun Jung, Lee Won Young, Oh Ki Won, Park Sung Woo, Kim Sun Woo, Park Cheol-Young
Primary Institution: Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea
Hypothesis
Does Sirt6 contribute to the protective effects of rosiglitazone on hepatic steatosis?
Conclusion
Rosiglitazone significantly decreased hepatic lipid accumulation, mediated by the activation of the Sirt6-AMPK pathway.
Supporting Evidence
- RGZ treatment improved hepatic lipid accumulation in rats.
- Sirt6 expression was increased by RGZ treatment.
- AMPK phosphorylation was enhanced by RGZ.
- Sirt6 knockdown increased hepatocyte lipid accumulation.
Takeaway
This study shows that a drug called rosiglitazone helps reduce fat in the liver of rats, and it does this by activating a protein called Sirt6.
Methodology
Rats were treated with rosiglitazone for 6 weeks, and the effects on liver fat and related proteins were analyzed.
Participant Demographics
Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats and age-matched Long-Evans Tokushima Otsuka (LETO) rats.
Statistical Information
P-Value
0.035
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website